SMO and neoplasm: However, concerns about the emergence of SMO mutants in the drug-binding pocket that are resistant to vismodegib and sonidegib50, as well as the limited demonstrated efficacy of vismodegib and sonidegib across broad tumor types, have highlighted the limitations of these SMO antagonists as Hh pathway inhibitors for clinical use.